125 related articles for article (PubMed ID: 6461944)
1. Prolongation of rat tail bleeding time caused by oral doses of a thromboxane synthetase inhibitor which have little effect on platelet aggregation.
Butler KD; Maguire ED; Smith JR; Turnbull AA; Wallis RB; White AM
Thromb Haemost; 1982 Feb; 47(1):46-9. PubMed ID: 6461944
[TBL] [Abstract][Full Text] [Related]
2. CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB
Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197
[TBL] [Abstract][Full Text] [Related]
3. In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat.
Maguire ED; Wallis RB
Thromb Res; 1983 Oct; 32(1):15-27. PubMed ID: 6689221
[TBL] [Abstract][Full Text] [Related]
4. The effects of a new thromboxane synthetase inhibitor, CGS-13080, in man.
MacNab MW; Foltz EL; Graves BS; Rinehart RK; Tripp SL; Feliciano NR; Sen S
J Clin Pharmacol; 1984; 24(2-3):76-83. PubMed ID: 6371062
[TBL] [Abstract][Full Text] [Related]
5. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
Dale J; Thaulow E; Myhre E; Parry J
Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
[TBL] [Abstract][Full Text] [Related]
6. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction.
De La Cruz JP; Villalobos MA; Escalante R; Guerrero A; Arrebola MM; Sánchez de La Cuesta F
Br J Pharmacol; 2002 Dec; 137(7):1082-8. PubMed ID: 12429581
[TBL] [Abstract][Full Text] [Related]
7. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
[TBL] [Abstract][Full Text] [Related]
8. Use of a thromboxane synthetase inhibitor, dazoxiben, during haemodialysis.
Dodd NJ; Gordge MP; Weston MJ
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):67S-70S. PubMed ID: 6337605
[TBL] [Abstract][Full Text] [Related]
9. Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma".
Bertelé V; Falanga A; Tomasiak M; Dejana E; Cerletti C; de Gaetano G
Science; 1983 Apr; 220(4596):517-9. PubMed ID: 6682245
[TBL] [Abstract][Full Text] [Related]
10. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
[TBL] [Abstract][Full Text] [Related]
11. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.
FitzGerald GA; Brash AR; Oates JA; Pedersen AK
J Clin Invest; 1983 Oct; 72(4):1336-43. PubMed ID: 6355181
[TBL] [Abstract][Full Text] [Related]
12. Thromboxane synthetase inhibition as antithrombotic strategy.
Vermylen J; Defreyn G; Carreras LO; Machin SJ; Van Schaeren J; Verstraete M
Lancet; 1981 May; 1(8229):1073-5. PubMed ID: 6112447
[TBL] [Abstract][Full Text] [Related]
13. Effects of Y-20811, a long-lasting thromboxane synthetase inhibitor, on thromboxane production and platelet function.
Mikashima H; Ochi H; Muramoto Y; Yasuda H; Tsuruta M; Maruyama Y
Thromb Res; 1986 Aug; 43(4):455-68. PubMed ID: 3094191
[TBL] [Abstract][Full Text] [Related]
14. Role of activated platelets in endotoxin-induced DIC in rats.
Ito T; Asai F; Oshima T; Kobayashi S
Thromb Res; 1990 Aug; 59(4):735-47. PubMed ID: 2080492
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of thromboxane synthetase inhibitors.
Smith JB
Fed Proc; 1987 Jan; 46(1):139-43. PubMed ID: 3542573
[TBL] [Abstract][Full Text] [Related]
16. Acute arterial thrombosis in rabbits: reduced platelet accumulation after treatment with thromboxane synthetase inhibitor dazoxiben hydrochloride, (UK-37, 248-01).
Randall MJ; Wilding RI
Thromb Res; 1982 Dec; 28(5):607-16. PubMed ID: 6897751
[TBL] [Abstract][Full Text] [Related]
17. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
Fitzpatrick FA; Gorman RR
Biochim Biophys Acta; 1978 Mar; 539(2):162-72. PubMed ID: 629996
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
19. The reduction of platelet thrombi on damaged vessel wall by a thromboxane synthetase inhibitor in rabbits.
Hall ER; Chen YC; Ho T; Wu KK
Thromb Res; 1982 Sep; 27(5):501-11. PubMed ID: 6891109
[TBL] [Abstract][Full Text] [Related]
20. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase.
Reilly IA; Doran JB; Smith B; FitzGerald GA
Circulation; 1986 Jun; 73(6):1300-9. PubMed ID: 2938849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
